Skip to main content

Novo Nordisk A/S

corporate_fare Company Profile

Novo Nordisk A/S

NVO·NYSE·Life Sciences·CIK 0000353278

Novo Nordisk A/S is a global healthcare company and a world leader in Obesity and Diabetes care. The company manufactures and markets pharmaceutical products and services. Its business activities originated from Nordisk Gentofte, established in 1923 by August Krogh, H. C. Hagedorn, and A. Kongsted, and Novo Industri A/S, established in 1925 by Harald and Thorvald Pedersen. From their inception, both companies focused on the production and sale of insulin for diabetes treatment. Headquartered in Denmark, Novo Nordisk employs more than 69,500 employees in around 80 countries and markets its products in approximately 170 countries. The company has a broad product portfolio across Obesity and Diabetes care and Rare disease. This includes a portfolio of glucagon-like-peptide-1 (GLP-1) receptor agonists for the treatment of obesity and diabetes, and modern and human insulins for the treatment of diabetes. During 2025, the company experienced continued growth across all therapy areas and in many geographic areas. However, due to increased competition in both US and ex-US markets, Novo Nordisk lost volume market share in the GLP-1 market for both obesity and diabetes. During 2025, there were periodic supply constraints for certain products in some markets, including Ozempic for the treatment of type 2 diabetes. The supply situation across products improved throughout 2025 due to continued scaling of manufacturing capabilities. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (NOVO-B), and its ADRs are listed on the New York Stock Exchange (NVO).

Novo Nordisk A/S (NYSE:NVO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for NVO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for NVO spans 6-K.

Recent high-impact activity:

  • Novo Lifts 2026 Outlook as Q3 Sales and Profit Beat, Wegovy Pill Sets Launch Record
  • Novo Raises 2026 Outlook as Q3 Adjusted Operating Profit Jumps 27% at CER
  • Novo Lifts Full-Year Outlook as Wegovy Pill Demand Beats Expectations
  • Judge Denies Novo Nordisk Bid to Halt Lilly's Weight-Loss Drug Ads
  • FDA Extends Denecimig Review; US Launch Slips to H1 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
kr309.06B DKK
Net Income
kr102.43B DKK
Diluted EPS
kr23.03 DKK
Op. Cash Flow
kr119.1B DKK
Free Cash Flow
kr58.96B DKK
Gross Profit
kr250.28B DKK
Operating Income
kr127.66B DKK
Cash & Equivalents
kr26.46B DKK
Total Debt
kr130.96B DKK
Debt / Equity
0.67×
Net Margin
33.1%
Shares Outstanding
4.44B sh
Source: 20-F · filed 2026-02-04 · accession 0000353278-26-000012

Short Interest & Short Volume

4.04 days to cover

FINRA reported short interest of 38,286,865 shares in NVO as of the October 30, 2026 settlement, a 2.3% increase from the prior period — about 4.0 days to cover at its recent average daily volume. On November 19, 2026, 28.8% of NVO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)38,286,865 shares as of October 30, 2026
Change vs prior period▲ 2.3%
Days to cover4.04 at avg daily volume of 9,466,850
Daily short volume (FINRA facilities)28.8% of 5,371,606 shares on November 19, 2026
5-day average short volume34.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

NVO files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with N →
$37.86 -2.60% today
52-week range · as of 2026-11-04 $35.12 – $64.16
Market cap
$171.96B
Volume
9.2M (0.8× avg)
3-mo avg 12M
Live data · 2026-11-20 20:38 UTC · Market open

show_chartPrice Chart

Loading chart...

feed NVO - Latest Insights

NVO
Nov 04, 2026, 8:35 AM EST
Source: Benzinga
Importance Score:
8
Price at Filing: $42.91
Real-time Price: $37.86 info
Change: -$5.05 (-12%) info
Market Cap: $171.957B info
NVO
Nov 04, 2026, 7:47 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $42.90
Real-time Price: $37.86 info
Change: -$5.04 (-12%) info
Market Cap: $171.957B info
NVO
Nov 04, 2026, 4:00 AM EST
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $41.96
Real-time Price: $37.86 info
Change: -$4.10 (-10%) info
Market Cap: $171.957B info
NVO
Oct 27, 2026, 3:10 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $39.16
Real-time Price: $37.86 info
Change: -$1.30 (-3%) info
Market Cap: $171.957B info
NVO
Oct 02, 2026, 5:53 PM EDT
Filing Type: 6-K
Importance Score:
8
Updated Oct 5, 12:49 PM ET — Novo Nordisk shares fell 1.17% to $36.88 on Monday following the FDA's extension of the denecimig review.
Price at Filing: $36.88
Real-time Price: $37.86 info
Change: +$0.980 (+3%) info
Market Cap: $171.957B info
NVO
Sep 29, 2026, 7:08 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $38.43
Real-time Price: $37.86 info
Change: -$0.570 (-1%) info
Market Cap: $171.957B info
NVO
Sep 29, 2026, 1:56 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $38.72
Real-time Price: $37.86 info
Change: -$0.8623 (-2%) info
Market Cap: $171.957B info
NVO
Sep 25, 2026, 3:11 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $38.64
Real-time Price: $37.86 info
Change: -$0.780 (-2%) info
Market Cap: $171.957B info
NVO
Sep 17, 2026, 12:21 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $42.97
Real-time Price: $37.86 info
Change: -$5.11 (-12%) info
Market Cap: $171.957B info
NVO
Sep 17, 2026, 7:28 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $41.87
Real-time Price: $37.86 info
Change: -$4.01 (-10%) info
Market Cap: $171.957B info
NVO
Aug 04, 2026, 5:23 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $44.37
Real-time Price: $37.86 info
Change: -$6.51 (-15%) info
Market Cap: $171.957B info
NVO
Aug 04, 2026, 1:40 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $43.87
Real-time Price: $37.86 info
Change: -$6.01 (-14%) info
Market Cap: $171.957B info
NVO
Jul 31, 2026, 8:54 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $47.64
Real-time Price: $37.86 info
Change: -$9.78 (-21%) info
Market Cap: $171.957B info
NVO
May 22, 2026, 2:32 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $44.77
Real-time Price: $37.86 info
Change: -$6.91 (-15%) info
Market Cap: $171.957B info
NVO
May 22, 2026, 10:01 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $44.56
Real-time Price: $37.86 info
Change: -$6.70 (-15%) info
Market Cap: $171.957B info
NVO
May 06, 2026, 7:51 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $47.96
Real-time Price: $37.86 info
Change: -$10.10 (-21%) info
Market Cap: $171.957B info
NVO
Apr 20, 2026, 6:50 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $40.29
Real-time Price: $37.86 info
Change: -$2.43 (-6%) info
Market Cap: $171.957B info
NVO
Mar 27, 2026, 6:33 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $36.58
Real-time Price: $37.86 info
Change: +$1.28 (+3%) info
Market Cap: $171.957B info
NVO
Mar 20, 2026, 8:11 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $36.36
Real-time Price: $37.86 info
Change: +$1.50 (+4%) info
Market Cap: $171.957B info
NVO
Feb 23, 2026, 6:28 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $40.45
Real-time Price: $37.86 info
Change: -$2.59 (-6%) info
Market Cap: $171.957B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets